ipamorelin clinical trials safety adverse effects CJC-1295 FDA Status: 2026 Compounding Guide ipamorelin clinical trials safety What

A typical course for peptides might be 3-6 months to target a specific goal, like healing the gut lining

Sternbeck, J., Sjdin,

Side Effects & Safety No lethal dose found -- toxicology studies couldn't establish an LD50 (Sikiric et al., 2006) No organ toxicity in chronic dosing No hormonal effects -- doesn't affect testosterone, estrogen, cortisol, or GH Mild nausea -- mostly with oral dosing Brief lightheadedness -- occasionally after injection Injection site redness -- standard for SC peptides Angiogenesis concern -- promotes new blood vessel growth, which raises a theoretical question about existing tumors

Brown et al., 2019) (Figure 2)